DeepMind Spinoff's AI-Designed Drugs Enter Human Trials
Isomorphic Labs, a spinoff from DeepMind, has advanced its AI-designed drugs to human trials. President Max Jaderberg announced at WIRED Health in London that the startup has developed a "broad and exciting pipeline of new medicines." The company leverages AI to accelerate drug discovery, potentially reducing the time and cost of bringing new treatments to market. This milestone marks a significant step in applying artificial intelligence to biotechnology, with implications for pharmaceutical innovation.
Key facts
- Isomorphic Labs is a spinoff from DeepMind.
- The startup's AI-designed drugs are headed to human trials.
- Max Jaderberg is president of Isomorphic Labs.
- Jaderberg spoke at WIRED Health in London.
- The pipeline includes a broad range of new medicines.
- AI is used to power drug discovery.
- The announcement was made at WIRED Health 2026.
- The technology aims to reduce time and cost in drug development.
Entities
Institutions
- Isomorphic Labs
- DeepMind
- WIRED
Locations
- London
- United Kingdom
Sources
- Wired AI —